S. C. Erridge

480 total citations
5 papers, 129 citations indexed

About

S. C. Erridge is a scholar working on Genetics, Cancer Research and Neurology. According to data from OpenAlex, S. C. Erridge has authored 5 papers receiving a total of 129 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 2 papers in Cancer Research and 1 paper in Neurology. Recurrent topics in S. C. Erridge's work include Glioma Diagnosis and Treatment (4 papers), Radiomics and Machine Learning in Medical Imaging (1 paper) and Cell Adhesion Molecules Research (1 paper). S. C. Erridge is often cited by papers focused on Glioma Diagnosis and Treatment (4 papers), Radiomics and Machine Learning in Medical Imaging (1 paper) and Cell Adhesion Molecules Research (1 paper). S. C. Erridge collaborates with scholars based in United Kingdom, Switzerland and Belgium. S. C. Erridge's co-authors include Roger Stupp, Monika E. Hegi, Kurt A. Jaeckle, M. R. Gilbert, Kenneth Aldape, Terri S. Armstrong, Minhee Won, Peter de Nully Brown, Aayushi Mahajan and Walter J. Curran and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Neuro-Oncology.

In The Last Decade

S. C. Erridge

4 papers receiving 128 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. C. Erridge United Kingdom	4	109	53	41	33	22	5	129
Liana Nobre Canada	8	110 1.0×	32 0.6×	45 1.1×	16 0.5×	21 1.0×	30	149
Kyle Wierzbicki United States	4	95 0.9×	34 0.6×	53 1.3×	75 2.3×	11 0.5×	4	129
Jinping Liu China	5	68 0.6×	32 0.6×	50 1.2×	33 1.0×	38 1.7×	9	150
Lihong Long United States	7	119 1.1×	42 0.8×	104 2.5×	66 2.0×	17 0.8×	12	191
Jiangfen Zhou China	6	46 0.4×	45 0.8×	56 1.4×	38 1.2×	16 0.7×	18	127
Tristan Penson United States	4	102 0.9×	55 1.0×	80 2.0×	26 0.8×	20 0.9×	5	198
Elke Pfaff Germany	4	84 0.8×	30 0.6×	48 1.2×	56 1.7×	7 0.3×	10	131
V. Golfinopoulos Belgium	5	110 1.0×	69 1.3×	22 0.5×	32 1.0×	26 1.2×	10	182
Niclas Colditz Netherlands	1	152 1.4×	49 0.9×	39 1.0×	22 0.7×	55 2.5×	2	170
Ian Robins United States	6	39 0.4×	29 0.5×	33 0.8×	22 0.7×	6 0.3×	9	85

Countries citing papers authored by S. C. Erridge

Since Specialization

Citations

This map shows the geographic impact of S. C. Erridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. C. Erridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. C. Erridge more than expected).

Fields of papers citing papers by S. C. Erridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. C. Erridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. C. Erridge. The network helps show where S. C. Erridge may publish in the future.

Co-authorship network of co-authors of S. C. Erridge

This figure shows the co-authorship network connecting the top 25 collaborators of S. C. Erridge. A scholar is included among the top collaborators of S. C. Erridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. C. Erridge. S. C. Erridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Tesileanu, C. Mircea S., Pim J. French, S. C. Erridge, et al.. (2020). CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA. Neuro-Oncology. 22(Supplement_2). ii47–ii47.

2.

Preusser, Matthias, Antonio Silvani, Émilie Le Rhun, et al.. (2019). PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology. 21(Supplement_3). iii2–iii3. 5 indexed citations

3.

Mehta, Minesh P., Kenneth Aldape, Roger Stupp, et al.. (2011). RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM). International Journal of Radiation Oncology*Biology*Physics. 81(2). S128–S129. 3 indexed citations

4.

Gilbert, M. R., Kenneth Aldape, Roger Stupp, et al.. (2011). RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology. 29(15_suppl). 2006–2006. 99 indexed citations

5.

Stupp, Roger, Martin J. van den Bent, S. C. Erridge, et al.. (2010). Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC).. Journal of Clinical Oncology. 28(15_suppl). TPS152–TPS152. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact